VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LGND
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LGNDLigand Pharmaceuticals Incorporated
$298.71$6.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLGNDFinancials

Ligand Pharmaceuticals Incorporated (LGND) Income Statement

30Y historyFree accessUpdated daily

Revenue swung from $115.5M in Q3 2025 to $51.7M in Q1 2026 and operating margin moved from 33.6% to -20.0% in Q3 2026, suggesting lumpy royalty recognition and thin operating conversion despite high gross margins near 96%.

Income StatementBalance SheetCash FlowRatios

LGND Income Statement

Annual statement

LGND Income Statement

Ligand Pharmaceuticals Incorporated (LGND) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue253.83M268.09M167.13M131.31M196.25M241.54M163.56M120.28M251.45M141.1M108.97M71.91M64.54M48.97M31.39M30.04M23.54M38.94M27.32M12.89M140.96M176.61M163.51M141.14M96.64M76.34M48.11M40.9M17.7M51.7M36.8M
Revenue Growth %1.03%60.4%27.28%-33.09%-18.75%47.68%35.98%-52.17%78.21%29.48%51.53%11.43%31.78%56.03%4.5%27.61%-39.55%42.56%111.84%-90.85%-20.18%8.01%15.85%46.05%26.59%58.68%17.63%131.07%-65.76%40.49%50.2%
Cost of Goods Sold-18.05M6.59M11.07M35.05M52.83M62.18M30.42M11.35M6.34M5.37M5.57M5.81M9.14M5.73M3.6M4.91M015.23M0022.64M39.85M39.8M31.62M20.31M13.95M1.62M3.1M-7.7M-9.8M-9.4M
COGS % of Revenue-2.46%6.63%26.69%26.92%25.74%18.6%9.43%2.52%3.8%5.11%8.07%14.16%11.71%11.47%16.34%-39.12%--16.06%22.56%24.34%22.4%21.01%18.27%3.36%7.58%-43.5%-18.96%-25.54%
Gross Profit271.88M261.5M156.06M96.27M143.42M179.37M133.14M108.94M245.12M135.74M103.4M66.11M55.4M43.24M27.79M25.13M23.54M23.7M27.32M12.89M118.32M136.76M123.71M109.52M76.33M62.39M46.49M37.8M25.4M61.5M46.2M
Gross Margin %107.11%97.54%93.37%73.31%73.08%74.26%81.4%90.57%97.48%96.2%94.89%91.93%85.84%88.29%88.53%83.66%100%60.88%100%100%83.94%77.44%75.66%77.6%78.99%81.73%96.64%92.42%143.5%118.96%125.54%
Gross Profit Growth %-67.56%62.11%-32.88%-20.04%34.72%22.22%-55.56%80.58%31.27%56.42%19.32%28.12%55.62%10.58%6.75%-0.7%-13.22%111.84%-89.1%-13.49%10.55%12.95%43.48%22.34%34.2%22.99%48.82%-58.7%33.12%63.83%
Operating Expenses241.64M214.3M178.66M84.32M140.38M75.52M95.64M-698.14M81.39M67.66M58.48M37.76M34.69M27.26M26.9M25.27M51.79M70.32M52.59M73.07M287.09M163.23M161.08M128.7M100.48M85.53M92.37M94.1M95M92.3M79.1M
OpEx % of Revenue-79.94%106.9%64.21%71.53%31.26%58.48%-580.42%32.37%47.95%53.67%52.5%53.75%55.66%85.7%84.12%220.03%180.58%192.54%566.69%203.67%92.43%98.51%91.19%103.98%112.04%192.01%230.07%536.72%178.53%214.95%
Selling, General & Admin147.6M92.45M78.65M52.79M70.06M46.79M60.01M41.88M37.73M28.65M26.62M24.38M22.57M17.98M16.11M14.98M29.72M15.21M23.79M30.41M248.28M107.16M95.88M61.02M41.68M34.43M34.11M27.3M16.6M10.1M10.2M
SG&A % of Revenue-34.48%47.06%40.2%35.7%19.37%36.69%34.82%15.01%20.31%24.43%33.9%34.97%36.72%51.32%49.86%126.28%39.06%87.08%235.85%176.14%60.68%58.63%43.23%43.13%45.1%70.91%66.75%93.79%19.54%27.72%
Research & Development23.09M81.18M21.43M24.54M36.08M32.1M40.5M55.91M27.86M26.89M21.22M13.38M12.12M9.27M10.79M10.29M22.07M39.87M30.77M44.62M41.93M56.08M65.2M67.68M58.81M51.1M51.29M59.4M70.7M72.4M59.5M
R&D % of Revenue-30.28%12.82%18.69%18.39%13.29%24.76%46.48%11.08%19.05%19.47%18.61%18.78%18.94%34.38%34.26%93.75%102.39%112.65%346.08%29.74%31.75%39.88%47.95%60.85%66.94%106.6%145.23%399.44%140.04%161.68%
Other Operating Expenses4M40.67M78.59M7M34.24M-3.38M-4.87M-795.93M15.79M12.12M10.64M0000000-1.96M-1.96M-3.12M000006.97M7.4M7.7M9.8M9.4M
Operating Income30.24M47.2M-22.61M11.94M3.04M103.85M37.5M807.08M163.73M68.08M43.88M27.33M19.63M14.94M574K-698K-29.3M-9.97M-97.28M-60.17M-168.77M-26.47M-37.37M-19.18M-24.15M-23.14M-45.88M-56.3M-69.6M-30.8M-32.9M
Operating Margin %11.91%17.61%-13.53%9.09%1.55%42.99%22.93%670.99%65.11%48.25%40.27%38%30.41%30.51%1.83%-2.32%-124.5%-25.6%-356.13%-466.69%-119.73%-14.99%-22.86%-13.59%-24.99%-30.31%-95.37%-137.65%-393.22%-59.57%-89.4%
Operating Income Growth %-308.79%-289.3%293.22%-97.08%176.94%-95.35%392.94%140.51%55.12%60.58%39.25%31.34%2503.31%182.23%97.62%-194.01%89.75%-61.66%64.34%-537.57%29.17%-94.86%20.59%-4.38%49.57%18.5%19.11%-125.97%6.38%-32.13%
EBITDA27.96M80.97M12.63M48.46M46.43M154.8M65.47M850.81M178.44M79.79M55.17M29.96M22.28M17.61M3.3M2.09M-27.09M-6.83M-96.22M-57.56M-152.55M-7.76M-22.1M-4.9M-13.68M-16.56M-38.91M-48.9M-61.9M-21M-23.5M
EBITDA Margin %11.02%30.2%7.56%36.91%23.66%64.09%40.03%707.34%70.97%56.55%50.63%41.66%34.53%35.95%10.52%6.96%-115.1%-17.55%-352.28%-446.41%-108.22%-4.4%-13.51%-3.47%-14.15%-21.7%-80.88%-119.56%-349.72%-40.62%-63.86%
EBITDA Growth %-45.93%540.97%-73.93%4.38%-70.01%136.45%-92.31%376.79%123.64%44.61%84.19%34.43%26.56%433.35%57.79%107.72%-296.49%92.9%-67.17%62.27%-1864.88%64.86%-351.12%64.19%17.42%57.43%20.43%21%-194.76%10.64%-10.85%
D&A (Non-Cash Add-back)26.05M33.77M35.24M36.52M43.39M50.95M27.97M43.73M14.72M11.71M11.29M2.63M2.66M2.66M2.73M2.79M2.21M3.13M1.05M2.62M16.22M18.71M15.28M14.28M10.47M6.57M6.97M7.4M7.7M9.8M9.4M
EBIT54.48M158.96M5.55M64.32M37.81M91.82M28.71M832.38M221.61M68.63M20.8M27.33M20.71M15.98M1.22M254K-15.35M-9.6M-97.31M-52.72M-78.08M-43.63M-15.38M-74.02M-43.85M-23.14M-45.88M-61.29M-69.6M-30.8M-32.9M
Net Interest Income17.66M8.94M5.02M7.05M247K-18.73M-19.34M-7.32M-34.28M-11.4M-12.18M-11.8M-4.86M-2.08M-2.92M-2.3M382K316K1.96M7.92M00000000000
Interest Income22.94M13.66M8.05M7.71M2.05M886K8.08M28.43M14M00000381K31K440K586K2.16M8.65M00000000000
Interest Expense5.28M4.71M3.04M656K1.8M19.62M27.41M35.74M48.28M11.4M12.18M11.8M4.86M2.08M3.31M2.51M58K270K202K735K00000000000
Other Income/Expense22.49M111.76M25.12M51.72M32.97M-31.65M-36.21M-10.44M9.6M-10.85M-35.92M8M-8.32M-5.74M-4.44M-2.86M13.9M95K-239K6.72M-96.19M-9.87M-7.54M-20.39M-8.36M-8.36M-825K-707K-43M-61.3M3.7M
Pretax Income52.73M158.96M2.52M63.66M36.01M72.2M1.29M796.64M173.33M57.23M7.96M35.33M11.3M9.21M-3.87M-2.93M-15.4M-9.87M-97.52M-53.46M-174.27M36.34M-44.91M-37.46M-32.6M-31.5M-46.71M-62M-112.6M-92.1M-29.2M
Pretax Margin %20.77%59.29%1.51%48.48%18.35%29.89%0.79%662.31%68.93%40.56%7.3%49.13%17.51%18.8%-12.31%-9.75%-65.44%-25.35%-357%-414.58%-123.63%20.58%-27.46%-26.54%-33.73%-41.26%-97.08%-151.59%-636.16%-178.14%-79.35%
Income Tax1.27M34.51M6.55M9.84M41.23M-4.15M-5.31M167.34M30.01M44.67M10.33M-219.6M410K374K-1.19M-13.1M-2.62M-7.92M-55K-18.7M-38.41M59K233K18.28M8.45M19.86M26.49M18.4M48.3M69.4M4.4M
Effective Tax Rate %2.41%21.71%260.13%15.46%114.49%-5.74%-410.68%21.01%17.31%78.06%129.74%-621.57%3.63%4.06%30.82%447.2%16.99%80.27%0.06%34.98%22.04%0.16%-0.52%-48.81%-25.91%-63.04%-56.72%-29.68%-42.9%-75.35%-15.07%
Net Income51.46M124.45M-4.03M52.15M-33.36M57.14M-2.98M629.3M143.32M12.56M-1.64M257.31M12.02M11.42M-527K10.18M-12.52M-1.95M-98.11M281.69M-31.74M-36.4M-45.14M-37.46M-32.6M-42.99M-72.38M-74.7M-117.9M-100.2M-37.3M
Net Margin %20.27%46.42%-2.41%39.72%-17%23.66%-1.82%523.19%57%8.9%-1.5%357.8%18.63%23.32%-1.68%33.88%-53.17%-5%-359.19%2184.64%-22.52%-20.61%-27.61%-26.54%-33.73%-56.32%-150.44%-182.64%-666.1%-193.81%-101.36%
Net Income Growth %5.93%3186.63%-107.73%256.33%-158.39%2014.17%-100.47%339.09%1041.45%867.48%-100.64%2039.93%5.28%2267.17%-105.18%181.31%-542.45%98.01%-134.83%987.4%12.79%19.37%-20.5%-14.93%24.19%40.59%3.11%36.64%-17.66%-168.63%41.9%
Net Income (Continuing)51.46M124.45M-4.03M53.82M-5.22M76.35M6.6M629.3M143.32M12.56M-2.37M227.44M10.89M8.83M-2.67M9.71M-12.79M-8.34M-97.46M-34.76M-56.59M-36.03M-45.14M-94.47M-52.26M-42.99M-59.28M-74.72M-117.9M-100.2M-37.3M
Discontinued Operations000-1.67M-28.14M-19.21M-9.58M000731K002.59M00000000000000000
Minority Interest000000000000-1.91M000000000000000000
EPS (Diluted)2.586.13-0.222.94-1.983.34-0.1831.855.960.53-0.0812.120.560.55-0.030.52-0.64-0.10-6.1617.22-2.36-2.95-3.68-3.18-2.83-4.34-7.80-9.51-17.51-18.15-7.78
EPS Growth %8.21%2886.36%-107.48%248.48%-159.28%1955.56%-100.57%434.4%1024.53%775.16%-100.65%2064.29%1.82%2175.47%-105.1%181.25%-540%98.38%-135.77%829.66%20%19.84%-15.72%-12.37%34.79%44.36%17.98%45.69%3.53%-133.29%54.74%
EPS (Basic)-6.44-0.223.02-1.983.46-0.1833.135.960.60-0.0813.000.590.56-0.030.52-0.64-0.10-6.1617.22-2.36-2.95-3.68-3.18-2.83-4.34-7.80-9.51-17.51-18.15-7.78
Diluted Shares Outstanding19.96M20.29M18.29M17.76M16.87M17.25M16.18M19.76M24.07M23.48M20.83M21.23M21.43M20.75M19.85M19.71M19.61M18.86M15.92M16.35M13.44M12.34M12.28M11.78M11.52M9.9M9.28M7.86M6.73M5.52M4.8M
Basic Shares Outstanding19.96M19.34M18.29M17.3M16.87M16.63M16.18M19M24.05M21.03M20.83M19.79M20.42M20.31M19.1M19.66M19.61M18.86M15.92M16.35M13.44M12.34M12.28M11.78M11.52M9.9M9.28M7.86M6.73M5.52M4.8M
Dividend Payout Ratio-------------------89.72%-----------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Royalty concentration in few assets

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Volatility Masks Underlying Royalty Momentum

Based on reported quarterly figures, LGND's revenue swung from $115.5M in Q3 2025 to $51.7M in Q1 2026, a pattern suggesting milestone timing and lumpy royalty recognition rather than a steady compounding trajectory.

The sequential swings indicate that headline revenue is heavily influenced by one-time milestone and Veklury-related items rather than a smooth royalty base. The management-cited 32% royalty growth year over year may reflect a firmer underlying trend, but the quarterly series alone does not confirm durable acceleration. Investors should monitor whether the Q2 2026 level of $63.7M can be sustained without further milestone support.

Gross Margin Structurally High, Operating Margin Thin

Reported gross margins of roughly 93% to 97% in most recent quarters, against operating margins swinging between -20.0% and 33.6%, suggest that the royalty model carries high gross economics but substantial and variable operating overhead.

The gap between gross and operating margin points to a cost base that is not scaling with the revenue line, which limits the operating leverage the royalty structure would otherwise imply. Quarters with negative operating margins likely reflect acquisition-related or R&D-type spending rather than core royalty erosion. The durability of the margin profile therefore depends on whether overhead can be held flat as revenue fluctuates.

Net Income Diverges Sharply From Operating Results

According to the reported income statement, LGND's Q3 2025 net income of $117.3M far exceeded its $54.9M operating income, and the Q2 2026 net margin of 76.2% also outpaces its 13.5% operating margin, suggesting large non-operating contributions.

Net income in several quarters appears driven by items below operating income, such as gains, tax effects, or other non-operating items, rather than core royalty earnings. Reported EPS therefore may overstate recurring earnings power in those periods. Analysts should strip these items out and rely on operating income or cash flow to assess the underlying profit base.

Stock Compensation Consumes Significant Earnings Capacity

Stock-based compensation ran at $18.2M in Q3 2026 and $13.7M in Q2 2026, which is material relative to quarterly operating income of $8.6M in Q2 2026, implying equity compensation absorbs a meaningful portion of the operating profit base.

Elevated stock-based compensation relative to operating income suggests that reported operating performance flatters the cash-economic cost of running the platform. Management's expense discipline appears uneven, with R&D spiking to $50.1M in Q1 2025 before falling sharply. Investors may wish to model SBC as a real cost when assessing sustainable margins.

Concentration Risk Could Undermine the Growth Narrative

Based on the supplied data, LGND's recent growth depends heavily on a small number of royalty assets, and a Q3 2026 operating loss of $15.8M following a Q2 2026 profit shows how quickly the earnings picture can reverse.

The bear case centers on whether recent royalty growth from Filspari and Veklury is durable once milestone and pandemic-era tailwinds fade. The swing to a -36.2% net margin in Q3 2026 suggests the earnings base is not yet stable enough to rely on single-quarter guidance. Warrants further investigation into the duration of key royalty streams before extrapolating the current growth rate.

LGND — Frequently Asked Questions

Quick answers to the most common questions about buying LGND stock.

What was Ligand Pharmaceuticals Incorporated's (LGND) revenue in 2025?

For fiscal year 2025, Ligand Pharmaceuticals Incorporated (LGND) reported total revenue of $268.1M. This represents a 628.5% increase compared to $36.8M in 1996.

Is Ligand Pharmaceuticals Incorporated (LGND) profitable?

Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $124.5M in net income for the fiscal year ending 2025 with a net profit margin of 46.4%.

What is Ligand Pharmaceuticals Incorporated's operating profit margin?

Ligand Pharmaceuticals Incorporated (LGND) reported an operating income of $47.2M, resulting in an operating profit margin of 17.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Ligand Pharmaceuticals Incorporated's gross profit and gross margin?

Ligand Pharmaceuticals Incorporated (LGND) generated $261.5M in gross profit for the year, representing a gross profit margin of 97.5%. This demonstrates the company's core pricing power and production efficiency.